Imaging Vascular Properties of Pediatric Brain Tumors Using DSC-MRI With Ferumoxytol (Code 7228) and DCE-MRI With Gadolinium in a Single Imaging Session: An NCI Sponsored Exploratory Trial
Patients will be scanned at five different time-points (5 MRI series). Each patient will
have a baseline MRI study (gadolinium only, with no ferumoxytol). MRI scans with both
ferumoxytol and gadolinium contrast will be performed beginning at least 3 weeks after the
baseline scan. The timing of all MRIs will not occur more frequently than every 3 weeks,
and all five ferumoxytol/gadolinium scans will take place within 2 years from study entry.
There will be a final outpatient clinic visit approximately 1 month after the final
Measurements such as size of tumor, blood flow to tumor (perfusion), and leakiness of blood
vessels within the tumor (permeability) will be described at each time-point and the
information will be evaluated throughout the study. The tumor size will be evaluated by 2
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Describe vascular properties of pediatric brain tumors using ferumoxytol for DSC-MRI and GBCA for DCE-MRI in a single MRI session. Describe evolving imaging characteristics of tumor vasculature using DSC-MRI with ferumoxytol and DCE-MRI with GBCA.
Edward A Neuwelt, MD
Oregon Health and Science University
United States: Food and Drug Administration
|Oregon Health & Science University||Portland, Oregon 97201|